Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Identifieur interne : 000619 ( PubMed/Corpus ); précédent : 000618; suivant : 000620Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Auteurs : Lisi Deng ; Chunna Li ; Qi Zeng ; Xi Liu ; Xinghua Li ; Haitang Zhang ; Zhongsi Hong ; Jinyu XiaSource :
- The Journal of infection [ 1532-2742 ] ; 2020.
Abstract
Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.
DOI: 10.1016/j.jinf.2020.03.002
PubMed: 32171872
Links to Exploration step
pubmed:32171872Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.</title><author><name sortKey="Deng, Lisi" sort="Deng, Lisi" uniqKey="Deng L" first="Lisi" last="Deng">Lisi Deng</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Chunna" sort="Li, Chunna" uniqKey="Li C" first="Chunna" last="Li">Chunna Li</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Qi" sort="Zeng, Qi" uniqKey="Zeng Q" first="Qi" last="Zeng">Qi Zeng</name><affiliation><nlm:affiliation>Cancer Center, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Xi" sort="Liu, Xi" uniqKey="Liu X" first="Xi" last="Liu">Xi Liu</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Xinghua" sort="Li, Xinghua" uniqKey="Li X" first="Xinghua" last="Li">Xinghua Li</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Haitang" sort="Zhang, Haitang" uniqKey="Zhang H" first="Haitang" last="Zhang">Haitang Zhang</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Hong, Zhongsi" sort="Hong, Zhongsi" uniqKey="Hong Z" first="Zhongsi" last="Hong">Zhongsi Hong</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: hongzhs@mail.sysu.edu.cn.</nlm:affiliation></affiliation></author><author><name sortKey="Xia, Jinyu" sort="Xia, Jinyu" uniqKey="Xia J" first="Jinyu" last="Xia">Jinyu Xia</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: xiajinyu@mail.sysu.edu.cn.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32171872</idno><idno type="pmid">32171872</idno><idno type="doi">10.1016/j.jinf.2020.03.002</idno><idno type="wicri:Area/PubMed/Corpus">000619</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000619</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.</title><author><name sortKey="Deng, Lisi" sort="Deng, Lisi" uniqKey="Deng L" first="Lisi" last="Deng">Lisi Deng</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Chunna" sort="Li, Chunna" uniqKey="Li C" first="Chunna" last="Li">Chunna Li</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zeng, Qi" sort="Zeng, Qi" uniqKey="Zeng Q" first="Qi" last="Zeng">Qi Zeng</name><affiliation><nlm:affiliation>Cancer Center, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Xi" sort="Liu, Xi" uniqKey="Liu X" first="Xi" last="Liu">Xi Liu</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Xinghua" sort="Li, Xinghua" uniqKey="Li X" first="Xinghua" last="Li">Xinghua Li</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Haitang" sort="Zhang, Haitang" uniqKey="Zhang H" first="Haitang" last="Zhang">Haitang Zhang</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</nlm:affiliation></affiliation></author><author><name sortKey="Hong, Zhongsi" sort="Hong, Zhongsi" uniqKey="Hong Z" first="Zhongsi" last="Hong">Zhongsi Hong</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: hongzhs@mail.sysu.edu.cn.</nlm:affiliation></affiliation></author><author><name sortKey="Xia, Jinyu" sort="Xia, Jinyu" uniqKey="Xia J" first="Jinyu" last="Xia">Jinyu Xia</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: xiajinyu@mail.sysu.edu.cn.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of infection</title><idno type="eISSN">1532-2742</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32171872</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J. Infect.</ISOAbbreviation></Journal><ArticleTitle>Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(20)30113-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2020.03.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.</AbstractText><CopyrightInformation>Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lisi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cancer Center, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinghua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haitang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Zhongsi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: hongzhs@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jinyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Fifth Affiliated Hospital, Sun Yat-sen University, 52 East Meihua Road, Zhuhai 519000, Guangdong Province, China. Electronic address: xiajinyu@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral intervention</Keyword><Keyword MajorTopicYN="N">Arbidol</Keyword><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Corona Virus Disease 2019</Keyword><Keyword MajorTopicYN="N">Lopinavir/ritonavir</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId><ArticleId IdType="pii">S0163-4453(20)30113-4</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7156152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):514-523</Citation><ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2002 Dec 4;532(1-2):107-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12459472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2008 Aug 23;372(9639):646-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18722869</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67</Citation><ArticleIdList><ArticleId IdType="pubmed">31573350</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drugs. 2003;63(8):769-802</Citation><ArticleIdList><ArticleId IdType="pubmed">12662125</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2016 Dec;71(12):3340-3350</Citation><ArticleIdList><ArticleId IdType="pubmed">27585965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Med Chem. 2008;15(10):997-1005</Citation><ArticleIdList><ArticleId IdType="pubmed">18393857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):692-694</Citation><ArticleIdList><ArticleId IdType="pubmed">31978293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000619 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000619 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32171872
|texte= Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32171872" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |